Anavex restates FY2025 internal control audit opinion, posts net loss of $46.38 million

AVXL•2026-08-28

Loss and cash position

Net loss was $46.38 million, or $0.54 per share; cash and cash equivalents ended at $102.58 million.

Management concluded disclosure controls were ineffective at Sept. 30, 2025; financial statements were not changed by the reassessment.

FY2025 filing updates internal control opinion

Anavex Life Sciences filed a 10-K/A with audited results for fiscal 2025, updating controls reporting tied to an internal control material weakness.

Grant Thornton’s audit kept an unqualified opinion on the consolidated financial statements, citing fair presentation under US GAAP. The auditor issued an adverse opinion on internal control over financial reporting as of Sept. 30, 2025, replacing a prior unqualified view.

Sources

Anavex restates FY2025 internal control audit opinion, posts net loss of $46.38 million

Sec

Anavex restates FY2025 internal control audit opinion, posts net loss of $46.38 million

Loss and cash position

FY2025 filing updates internal control opinion

Related News

Crinetics Pharmaceuticals held special shareholder meeting on merger proposal vote

First Breach net loss widens 520% to $13.88 million in Q2 FY26

IonQ appoints Eric Ball, Timothy Baxter to board of directors

Sources

Anavex restates FY2025 internal control audit opinion, posts net loss of $46.38 million

SRX Global sells 3,579 Series C preferred shares in private placement valued at $2.86 million

Socket Mobile falls below Nasdaq $2.5 million stockholders’ equity minimum, risks delisting notice